Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.

OBJECTIVE To compare the efficacy and safety of 2 treatment modalities, topical psoralen plus UV-A (PUVA) with unsubstituted psoralen and 311-nm UV-B radiation, in patients with vitiligo. DESIGN This intervention study was designed as a before-and-after trial with 2 arms, in which patients were consecutively included. PATIENTS Male (n = 99) and female (n = 182) patients, who predominantly had skin type III, with extensive, generalized vitiligo of more than 3 months' duration. INTERVENTIONS Two patient groups were investigated. The first group of patients was treated for 4 months with either topical PUVA (n = 28) or 311-nm UV-B radiation (n = 78). The second group of patients, treated twice weekly with 311-nm UV-B radiation, was followed up for 3 (n = 60), 6 (n = 27), 9 (n = 37), or 12 months (n = 51). RESULTS Thirteen (46%) patients in the first group treated with topical PUVA showed repigmentation after 4 months. Fifty-two patients (67%) in the 311-nm UV-B treatment group showed repigmentation after 4 months. After 3 months, 5 patients (8%) in the second group showed more than 75% repigmentation of lesional skin compared with 32 patients (63%) after 12 months. As in other treatment modalities, the face showed good repigmentation, whereas hands and feet responded poorly. No adverse effects were encountered with treatment with narrowband UV-B radiation, contrary to those seen with topical PUVA treatment. The cumulative UV-B dose was very small compared with that of the topical PUVA treatment. CONCLUSIONS According to our results, the treatment of patients with vitiligo with 311-nm UV-B radiation is as efficient as with topical PUVA and has fewer adverse effects.

[1]  E. Frenk,et al.  Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin. , 1987, Dermatologica.

[2]  R. Stern,et al.  Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. , 1979, The New England journal of medicine.

[3]  R. Halder,et al.  Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. , 1995, Archives of dermatology.

[4]  N. Lowe,et al.  PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. , 1986, Journal of the American Academy of Dermatology.

[5]  D. Buckley,et al.  Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo , 1996, Clinical and experimental dermatology.

[6]  G. Nicolson,et al.  Asymmetries in Compact Sources at 2,298 MHz , 1972 .

[7]  T. Fitzpatrick,et al.  Vitiligo and Other Hypomelanoses of Hair and Skin , 1983, Topics in Dermatology.

[8]  J. C. Leun,et al.  A new development in UVB phototherapy of psoriasis , 1988, The British journal of dermatology.

[9]  J. C. van der Leun,et al.  Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. , 1990, Acta dermato-venereologica.

[10]  B. Johnson,et al.  Melanin and cellular reactions to ultraviolet radiation. , 1972, Nature: New biology.

[11]  W. Westerhof,et al.  A new psoralen‐containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque‐type psoriasis, and hyperkeratotic eczema , 1995, The British journal of dermatology.

[12]  V. Neild,et al.  Plasma levels of 8‐methoxypsoralen in psoriatic patients receiving topical 8‐methoxypsoralen , 1982, The British journal of dermatology.